학술논문
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Document Type
article
Author
Olga Kondrashova; Monique Topp; Ksenija Nesic; Elizabeth Lieschke; Gwo-Yaw Ho; Maria I. Harrell; Giada V. Zapparoli; Alison Hadley; Robert Holian; Emma Boehm; Valerie Heong; Elaine Sanij; Richard B. Pearson; John J. Krais; Neil Johnson; Orla McNally; Sumitra Ananda; Kathryn Alsop; Karla J. Hutt; Scott H. Kaufmann; Kevin K. Lin; Thomas C. Harding; Nadia Traficante; Australian Ovarian Cancer Study (AOCS); Anna deFazio; Iain A. McNeish; David D. Bowtell; Elizabeth M. Swisher; Alexander Dobrovic; Matthew J. Wakefield; Clare L. Scott
Source
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
Subject
Language
English
ISSN
2041-1723
Abstract
Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC.